RayzeBio (RYZB) Long Term Liabilities

Annual Total Long Term Liabilities

N/A

September 1, 2023


Summary


Performance

RYZB Long Term Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

Earnings dates

OtherRYZBbalance sheetmetrics:

Quarterly Long Term Liabilities

$11.08 M
-$415.51 M-97.40%

September 30, 2023


Summary


Performance

RYZB Quarterly Long Term Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

Earnings dates

OtherRYZBbalance sheetmetrics:

Long Term Liabilities Formula

Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities

RYZB Long Term Liabilities Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year--
3 y3 years--
5 y5 years--

RYZB Long Term Liabilities Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-97.4%at low
5 y5-year-97.4%at low
alltimeall time-97.4%at low

RayzeBio Long Term Liabilities History

DateAnnualQuarterly
Sep 2023
-
$11.08 M(-97.4%)
Jun 2023
-
$426.59 M(+0.2%)
DateAnnualQuarterly
Dec 2022
$425.61 M(+60.7%)
$425.61 M
Dec 2021
$264.82 M(+76.8%)
-
Dec 2020
$149.78 M
-

FAQ

  • What is the all time high annual total long term liabilities for RayzeBio?
  • What is RayzeBio quarterly total long term liabilities?
  • What is the all time high quarterly long term liabilities for RayzeBio?

What is the all time high annual total long term liabilities for RayzeBio?

RayzeBio all-time high annual total long term liabilities is $425.61 M

What is RayzeBio quarterly total long term liabilities?

The current quarterly long term liabilities of RYZB is $11.08 M

What is the all time high quarterly long term liabilities for RayzeBio?

RayzeBio all-time high quarterly total long term liabilities is $426.59 M